Table 3. Comparative antigenicity of gp120Ba-L expressed in 293T cells in the presence or absence of 5 µM kifunensine.
Numbers shown indicated the fold increase or decrease in the 50% binding titer for the gp120Ba-L expressed in the presence of kifunensine compared to that produced in untreated cells. Bold type indicates a statistically significant difference (P < 0.05). Where the 50% binding titer did not fall within the range of ligand utilized, the fold-difference in absorbance at the maximal concentration of ligand is reported in parentheses. Epitope 1 – V3-loop; 2 – glycans; 3 – CD4bs; 4 –all regions (polyclonal immunoglobulin from HIV-1-infected patients or rabbit antisera to gp120).
Ligand | Epitope | Kifunensine |
---|---|---|
19b | 1 | 3.43 |
447-52D | 1 | 0.80 |
2G12 | 2 | 3.08 |
b12 | 3 | 82.06 |
F105 | 3 | 4.73 |
CD4-IgG2 | 3 | 6.08 |
15e | 3 | (9.14) |
21h | 3 | (0.96) |
HIVIg | 4 | 1.46 |
ARP440 | 4 | 1.38 |